Stifel resumed coverage of Celcuity (CELC) with a Buy rating and $30 price target Stifel views gedatolisib as a uniquely differentiated asset poised to emerge as a standard-of-care treatment option within an increasingly competitive 2L+ HR+/HER2- metastatic breast cancer development landscape and thinks preclinical data clearly establishes gedatolisib’s enhanced potency vs. single-node PI3K/AKT/mTOR signaling pathway inhibitors, the analyst tells investors in a research note. The firm believes Q3 topline VIKTORIA-1 mPFS data in PIK3CA-wild-type patients represents favorable risk/reward at current valuation
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CELC:
- Promising Preliminary Data and Positive Outlook for Celcuity’s Gedatolisib in Cancer Trials
- Celcuity Announces Promising Phase 1 Gedatolisib Results
- Celcuity reports clinical data from two early phase studies of gedatolisib
- Celcuity’s Promising Clinical Trials and Strong Financial Position Justify Buy Rating
- Celcuity Approves Stock Plan Amendment at Annual Meeting